UP 446 botanical extract (Unigen) reduces pain scores in Osteoarthritis

In a randomised, double blind, placebo study, 60 people aged between 45 and 75 years were given, in the first group, placebo,in the second and third groups given 250 mg and 500mg per day of the botanical extract UP 446 from Unigen and in the fourth group were given 200 mg per day of celecoxib for 90 days. Results showed that WOMAC pain scores were reduced in both botanical extract groups and the celecoxib group but with no change in the placebo group. In addition, the botanical group experienced reductions of functional impairment scores and there were no such improvements in either the placebo group or the celecoxib group,. see Nutrition Jo. 2012, 11:21, doi: 10.1186/1475-2891-11-21 "A randomised double blind placebo and active comparator controlled pilot study of UP 446 a novel dual pathway inhibitor anti inflammatory agent of botanical origin". J.Sampalis, L.A. Brownell